{"schema_version":"secwatch.filing_event.v1","accession":"0000914475-23-000005","form_type":"8-K","ticker":"NBIX","cik":"0000914475","company_name":"NEUROCRINE BIOSCIENCES INC","filed_at":"2023-02-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:48.531636+00:00","generated_at":"2026-06-20T00:41:45.365090+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Neurocrine Q4 INGREZZA sales $399M; guides FY23 INGREZZA $1.67-1.77B","bullets":["Q4 2022 INGREZZA net product sales $399M (+33% YoY); full year $1.43B.","GAAP net income $89M ($0.88 diluted EPS) vs loss year-ago; non-GAAP net income $125M ($1.24 EPS).","FY2023 INGREZZA sales guidance $1.67-1.77B (tardive dyskinesia only); GAAP R&D $550-580M, SG&A $850-870M.","PDUFA date Aug 20, 2023 for valbenazine in Huntington chorea; crinecerfont registrational studies enrollment complete.","Acquired Diurnal Group (~$55M) Nov 2022; entered Voyager partnership for GBA1 gene therapy Jan 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000914475-23-000005","json":"https://secwatch.observer/filing/0000914475-23-000005.json","markdown":"https://secwatch.observer/filing/0000914475-23-000005.md","text":"https://secwatch.observer/filing/0000914475-23-000005.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/914475/000091447523000005/0000914475-23-000005-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/914475/000091447523000005/nbix-20230206.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T00:41:45.365090+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"586cc380687cb74f8c5da6b22767247215521a14","claim":"NEUROCRINE BIOSCIENCES INC reported financial results for the fourth quarter and fiscal year ended December 31, 2022.","evidence_excerpt":"On February 6, 2023, Neurocrine Biosciences, Inc. announced its financial results for the fourth quarter and fiscal year ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/914475/000091447523000005/0000914475-23-000005-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and fiscal year ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}